secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001723128-24-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q1 revenue $659M (+18% YoY); GAAP net loss $92M on $94M opioid charge
----------------------------------------------------------------------------

- Net revenue $659M (+18% YoY); Generics +14%, Specialty +15%, AvKARE +33%.
- GAAP net loss $92M ($0.30 loss per share) includes $94M pre-tax charge for nationwide opioids settlement in principle.
- Adjusted EBITDA $152M (+31% YoY); adjusted diluted EPS $0.14 (vs $0.12 YoY).
- Opioids settlement payable over ten years; company affirming 2024 full-year guidance.
- All three segments posted double-digit revenue growth for first time in same quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/0001723128-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/amrx-20240503.htm
  HTML page:      https://secwatch.observer/filing/0001723128-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer